Cargando…

Gastrointestinal symptoms in low-dose aspirin users: a comparison between plain and buffered aspirin

BACKGROUND: Aspirin is associated with gastrointestinal side effects such as gastric ulcers, gastric bleeding and dyspepsia. High-dose effervescent calcium carbasalate (ECC), a buffered formulation of aspirin, is associated with reduced gastric toxicity compared with plain aspirin in healthy volunte...

Descripción completa

Detalles Bibliográficos
Autores principales: Jaspers Focks, J., Tielemans, M. M., van Rossum, L. G. M., Eikendal, T., Brouwer, M. A., Jansen, J. B. M. J., Laheij, R. J. F., Verheugt, F. W. A., van Oijen, M. G. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bohn Stafleu van Loghum 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931859/
https://www.ncbi.nlm.nih.gov/pubmed/24522950
http://dx.doi.org/10.1007/s12471-014-0522-3
_version_ 1782304726648356864
author Jaspers Focks, J.
Tielemans, M. M.
van Rossum, L. G. M.
Eikendal, T.
Brouwer, M. A.
Jansen, J. B. M. J.
Laheij, R. J. F.
Verheugt, F. W. A.
van Oijen, M. G. H.
author_facet Jaspers Focks, J.
Tielemans, M. M.
van Rossum, L. G. M.
Eikendal, T.
Brouwer, M. A.
Jansen, J. B. M. J.
Laheij, R. J. F.
Verheugt, F. W. A.
van Oijen, M. G. H.
author_sort Jaspers Focks, J.
collection PubMed
description BACKGROUND: Aspirin is associated with gastrointestinal side effects such as gastric ulcers, gastric bleeding and dyspepsia. High-dose effervescent calcium carbasalate (ECC), a buffered formulation of aspirin, is associated with reduced gastric toxicity compared with plain aspirin in healthy volunteers, but at lower cardiovascular doses no beneficial effects were observed. AIM: To compare the prevalence of self-reported gastrointestinal symptoms between low-dose plain aspirin and ECC. METHODS: A total of 51,869 questionnaires were sent to a representative sample of the Dutch adult general population in December 2008. Questions about demographics, gastrointestinal symptoms in general and specific symptoms, comorbidity, and medication use including bioequivalent doses of ECC (100 mg) and plain aspirin (80 mg) were stated. We investigated the prevalence of self-reported gastrointestinal symptoms on ECC compared with plain aspirin using univariate and multivariate logistic regression analyses. RESULTS: A total of 16,715 questionnaires (32 %) were returned and eligible for analysis. Of these, 911 (5 %) respondents reported the use of plain aspirin, 633 (4 %) ECC and 15,171 reported using neither form of aspirin (91 %). The prevalence of self-reported gastrointestinal symptoms in general was higher in respondents using ECC (27.5 %) compared with plain aspirin (26.3 %), but did not differ significantly with either univariate (OR 1.06, 95 %CI 0.84–1.33), or multivariate analysis (aOR 1.08, 95 %CI 0.83–1.41). Also, none of the specific types of symptoms differed between the two aspirin formulations. CONCLUSIONS: In this large cohort representative of the general Dutch population, low-dose ECC is not associated with a reduction in self-reported gastrointestinal symptoms compared with plain aspirin. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s12471-014-0522-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-3931859
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Bohn Stafleu van Loghum
record_format MEDLINE/PubMed
spelling pubmed-39318592014-02-28 Gastrointestinal symptoms in low-dose aspirin users: a comparison between plain and buffered aspirin Jaspers Focks, J. Tielemans, M. M. van Rossum, L. G. M. Eikendal, T. Brouwer, M. A. Jansen, J. B. M. J. Laheij, R. J. F. Verheugt, F. W. A. van Oijen, M. G. H. Neth Heart J Original Article BACKGROUND: Aspirin is associated with gastrointestinal side effects such as gastric ulcers, gastric bleeding and dyspepsia. High-dose effervescent calcium carbasalate (ECC), a buffered formulation of aspirin, is associated with reduced gastric toxicity compared with plain aspirin in healthy volunteers, but at lower cardiovascular doses no beneficial effects were observed. AIM: To compare the prevalence of self-reported gastrointestinal symptoms between low-dose plain aspirin and ECC. METHODS: A total of 51,869 questionnaires were sent to a representative sample of the Dutch adult general population in December 2008. Questions about demographics, gastrointestinal symptoms in general and specific symptoms, comorbidity, and medication use including bioequivalent doses of ECC (100 mg) and plain aspirin (80 mg) were stated. We investigated the prevalence of self-reported gastrointestinal symptoms on ECC compared with plain aspirin using univariate and multivariate logistic regression analyses. RESULTS: A total of 16,715 questionnaires (32 %) were returned and eligible for analysis. Of these, 911 (5 %) respondents reported the use of plain aspirin, 633 (4 %) ECC and 15,171 reported using neither form of aspirin (91 %). The prevalence of self-reported gastrointestinal symptoms in general was higher in respondents using ECC (27.5 %) compared with plain aspirin (26.3 %), but did not differ significantly with either univariate (OR 1.06, 95 %CI 0.84–1.33), or multivariate analysis (aOR 1.08, 95 %CI 0.83–1.41). Also, none of the specific types of symptoms differed between the two aspirin formulations. CONCLUSIONS: In this large cohort representative of the general Dutch population, low-dose ECC is not associated with a reduction in self-reported gastrointestinal symptoms compared with plain aspirin. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s12471-014-0522-3) contains supplementary material, which is available to authorized users. Bohn Stafleu van Loghum 2014-02-13 2014-03 /pmc/articles/PMC3931859/ /pubmed/24522950 http://dx.doi.org/10.1007/s12471-014-0522-3 Text en © The Author(s) 2014 https://creativecommons.org/licenses/by/2.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Article
Jaspers Focks, J.
Tielemans, M. M.
van Rossum, L. G. M.
Eikendal, T.
Brouwer, M. A.
Jansen, J. B. M. J.
Laheij, R. J. F.
Verheugt, F. W. A.
van Oijen, M. G. H.
Gastrointestinal symptoms in low-dose aspirin users: a comparison between plain and buffered aspirin
title Gastrointestinal symptoms in low-dose aspirin users: a comparison between plain and buffered aspirin
title_full Gastrointestinal symptoms in low-dose aspirin users: a comparison between plain and buffered aspirin
title_fullStr Gastrointestinal symptoms in low-dose aspirin users: a comparison between plain and buffered aspirin
title_full_unstemmed Gastrointestinal symptoms in low-dose aspirin users: a comparison between plain and buffered aspirin
title_short Gastrointestinal symptoms in low-dose aspirin users: a comparison between plain and buffered aspirin
title_sort gastrointestinal symptoms in low-dose aspirin users: a comparison between plain and buffered aspirin
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931859/
https://www.ncbi.nlm.nih.gov/pubmed/24522950
http://dx.doi.org/10.1007/s12471-014-0522-3
work_keys_str_mv AT jaspersfocksj gastrointestinalsymptomsinlowdoseaspirinusersacomparisonbetweenplainandbufferedaspirin
AT tielemansmm gastrointestinalsymptomsinlowdoseaspirinusersacomparisonbetweenplainandbufferedaspirin
AT vanrossumlgm gastrointestinalsymptomsinlowdoseaspirinusersacomparisonbetweenplainandbufferedaspirin
AT eikendalt gastrointestinalsymptomsinlowdoseaspirinusersacomparisonbetweenplainandbufferedaspirin
AT brouwerma gastrointestinalsymptomsinlowdoseaspirinusersacomparisonbetweenplainandbufferedaspirin
AT jansenjbmj gastrointestinalsymptomsinlowdoseaspirinusersacomparisonbetweenplainandbufferedaspirin
AT laheijrjf gastrointestinalsymptomsinlowdoseaspirinusersacomparisonbetweenplainandbufferedaspirin
AT verheugtfwa gastrointestinalsymptomsinlowdoseaspirinusersacomparisonbetweenplainandbufferedaspirin
AT vanoijenmgh gastrointestinalsymptomsinlowdoseaspirinusersacomparisonbetweenplainandbufferedaspirin